glp·helper
glphelper.com/mounjaro/michigan/pontiac
Dual GIP / GLP-1 receptor agonistFDA-approved May 2022Rx · Subcutaneous injection · Once weekly

Mounjaro® providers &
prescriptions in Pontiac, MI

Dr. Fahad Akhtar, M.D.
Medically reviewed by Dr. Fahad Akhtar, M.D.
Physician at g1v.me, an affiliated practice

Mounjaro is FDA-approved for type 2 diabetes, not for weight management.[1] The tirzepatide approved for chronic weight management is Zepbound in Pontiac.

Physicians near Pontiac, MI from the federal NPI registry. Ask each office whether it prescribes Mounjaro.[9]

city providers
27
as of today

Same molecule (tirzepatide): Tirzepatide in Pontiac, Zepbound in Pontiac

Other GLP-1 medicines: Ozempic in Pontiac, Wegovy in Pontiac, Semaglutide in Pontiac

§ 02Provider directory: Michigan
27 of 27 shown

Find a Mounjaro provider in Pontiac.

Every entry comes from the federal NPI registry. Ask each office what it prescribes. We do not accept payment for placement.

Filter →
Type
Provider
City
Insurance / phone
Mounjaro by Michigan town, physicians per town
§ 03Getting Mounjaro in Pontiac
27 providers · Pontiac, MI

How to get Mounjaro in Pontiac.

27 GLP-1 prescribers and 6 local resource types are on record for Pontiac, plus 3 nearby towns in the directory.

Physicians in Pontiac
27 physicians
27 physicians from the federal NPI registry in Pontiac, most listed as Internal Medicine (13), Family Medicine (13) and Family Medicine, Sports Medicine (1). A licensed clinician who evaluates you decides whether an FDA-approved GLP-1 fits. Telehealth rules vary by state. The nearest towns on record are Rochester Hills (33 providers), Troy (17 providers) and Royal Oak (31 providers).
Around the prescription in Pontiac
6 listed nearby
9 dietitians, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near Pontiac.
Medicaid (weight loss)
Limited
As of April 2026, Michigan Medicaid covers GLP-1s for weight loss only in limited cases (morbid obesity only, after other treatments fail). Diabetes coverage is broader. Employer and private plans vary by plan.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Michigan’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for adults with type 2 diabetes. Same molecule as Zepbound.

Mounjaro is the brand name Eli Lilly uses for tirzepatide approved for type 2 diabetes. It is a once-weekly subcutaneous injection and the first approved dual GIP/GLP-1 receptor agonist. It activates two gut-hormone pathways rather than one. The identical molecule, marketed as Zepbound, is the FDA-approved formulation for chronic weight management.[2][3]

In the SURPASS-2 head-to-head trial, tirzepatide produced greater HbA1c reductions and greater weight loss than semaglutide 1 mg across all doses. Across the SURPASS program, tirzepatide lowered HbA1c by approximately 1.8 to 2.6 percentage points. Mounjaro is approved as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes.[1]

Bar chart of Mounjaro dose strengths on the FDA label: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg
Mounjaro comes in 6 strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg. The chart shows what the label lists. A prescriber sets the dose.[1]
At a glanceMultiple (per dose)
Active ingredient
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
May 2022
Approved use
Type 2 diabetes mellitus (adults)
Off-label use
Not FDA-approved for weight management. Zepbound is the tirzepatide approved for it
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in Pontiac

Pontiac, Michigan has a population of 61,606 people. The adult obesity rate in Pontiac is an age-adjusted estimate of 43.5%, 7.4 percentage points above the Michigan state rate of 36.1%. Diagnosed diabetes reaches 15.9% of adults in Pontiac. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 33.9% of adults in Pontiac.

of Pontiac adults have obesity
43.5%
diagnosed diabetes
15.9%
no regular physical activity
33.9%

Age-adjusted estimates for Pontiac, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossOzempic side effects in men
§ 05Support around Mounjaro in Pontiac
6 gyms

The prescription is one part. Here is the rest, in Pontiac.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Pontiac, MI, ordered as the registry lists them, never by who pays us.

Gyms near you

A gym gives you the regular movement that keeps muscle while the weight comes off.

Crunch Fitness - Waterford
GYM
4.1 on Google · 484 reviews
4998 Dixie Hwy
Website
Planet Fitness
GYM
4.5 on Google · 433 reviews
4030 Baldwin Rd
Website
Planet Fitness
GYM
4.2 on Google · 275 reviews
1935 S Telegraph Rd
Website
Life Time
GYM
4.2 on Google · 239 reviews
4106 Telegraph Rd
Website
Xceleration Fitness
GYM
4.9 on Google · 190 reviews
2675 Lapeer Rd
Website
Fully Tapped Fitness
GYM
4.9 on Google · 165 reviews
3770 Dixie Hwy
Website

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Mackenzie Bruce, RDN
RD
Registered dietitian
44200 Woodward Ave Ste 209
Call 248-253-0330NPI 1306483037
Mariela Cruz Rodriguez
RD
Registered dietitian
461 W Huron St
Call 248-724-7443NPI 1780270462
Alexandra Evink, RD
RD
Registered dietitian
44200 Woodward Ave Ste 209
Call 248-253-0330NPI 1831950732
Megan Krings
RD
Registered dietitian
114 Orchard Lake Rd
Call 248-724-7600NPI 1710570759
Amber Spencley, RDN
RD
Registered dietitian
461 W Huron St Ste 107
Call 248-724-7600NPI 1932661592
Rosemarie Stauber
RD
Registered dietitian
461 W Huron St Ste 107
Call 248-724-7600NPI 1447997531
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURPASS diabetes program, including the SURPASS-2 head-to-head against semaglutide. Figures are means at each trial's primary endpoint.

Across the SURPASS program, tirzepatide reduced HbA1c by approximately 1.8 to 2.6 percentage points and produced substantial weight loss, outperforming insulin and GLP-1 comparators. Mounjaro is approved as an adjunct to diet and exercise for glycemic control in adults with T2D.[4]
STEP / SELECT endpoint table2.4 mg / 68 wk
HbA1c reduction (T2D)
−1.8 to −2.6%
SURPASS program[4]
vs. semaglutide 1 mg
Superior
SURPASS-2, HbA1c + weight[3]
Mean weight change (15 mg, obesity)
−20.9%
SURMOUNT-1, 72 wk (Zepbound)[2]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Mounjaro weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most Mounjaro side effects are stomach and gut effects.

In Mounjaro's diabetes trials at 5 to 15 mg, the most common side effects were nausea (12 to 18%), diarrhea (12 to 17%), decreased appetite (5 to 11%), and vomiting (5 to 9%). Most reports came during dose escalation and decreased over time.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[1]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12 to 18%
mild
Most reports came during dose escalation and decreased over time
Diarrhea
12 to 17%
mild
More frequent during dose escalation
Vomiting
5 to 9%
mild
Reduced by slower titration
Constipation
6 to 7%
mild
Decreased appetite
5 to 11%
mild
Expected pharmacologic effect
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

What Mounjaro costs, by how you pay.

The price you pay depends on your insurance plan, your diagnosis, and how you buy. Manufacturer self-pay programs cost far less than pharmacy retail. Here are the ranges.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Eli Lilly self-pay and savings pages.

Self-pay and savings card prices checked . Retail averages from May 2026.

Mounjaro monthly cost by how you pay
Pharmacy retail (no insurance)$1,000 to $1,200per monthBrand-name retail average, May 2026[6]
LillyDirect self-payfrom $499per monthListed at the same starting price for every strength, 2.5 mg to 15 mg
Commercial insurance (T2D)$25 to $250per month copayUsually covered for diabetes with prior authorization
Medicare Part D$0 to $100per monthT2D covered; weight-loss indication not covered by law[5]
Manufacturer savings cardas low as $25per monthCommercial insurance only; eligibility limits apply
Find Mounjaro providers in Pontiac

Physicians from the federal NPI registry. Ask each office whether it prescribes Mounjaro.

Mounjaro in other states

Physicians from the federal NPI registry in the states we cover. Ask each office whether it prescribes Mounjaro.

Related GLP-1 research
§ 09Frequently asked: Mounjaro in Michigan

The questions people ask before they book.

Answers reviewed by the glp·helper Medical Team. Citations link to primary sources, never marketing copy.

Mounjaro and Zepbound are both tirzepatide, made by Eli Lilly, but they carry different FDA-approved indications. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. Insurers treat them as separate products, and coverage differs sharply between the two.[1]